CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Vaxcyte, Inc.

PCVX
$7.43B
Mid Cap
NASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaSAN CARLOS414 employees

Drugs in Pipeline

7

Phase 3 Programs

3

Upcoming Catalysts

5

Next Catalyst

Aug 5, 2026

8d

Market Overview

Stock performance and key metrics

PCVX News
Catalyst Timeline

5 upcoming, 0 past

EarningsNext

PCVX Earnings Report

Aug 5, 2026

EPS Est: $-1.47 | FQ end 2026-06

4 more catalysts beyond 14 days

Start a 48-hour free trial to see all upcoming catalysts

Pro

How PCVX's past catalysts played out

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Market-Implied Move
Regulatory Approvals

Frequently asked questions

What is in Vaxcyte, Inc.'s drug pipeline?

CatalystAlert tracks 7 drug candidates in Vaxcyte, Inc.'s (PCVX) pipeline across Phase 3, Phase 2. Its lead program is 31 valent pneumococcal conjugate vaccine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Vaxcyte, Inc.'s next FDA catalyst?

Vaxcyte, Inc.'s (PCVX) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track PCVX biotech catalysts?

Add PCVX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Vaxcyte, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply